Odyssey plans ulcerative colitis trial of dual immune blockade
Odyssey plans a global Phase 2a trial pairing an innate-immune inhibitor with vedolizumab for moderate-to-severe ulcerative colitis. Topline induction results are expected in the second half of 2027.